For this purpose, we selected the three proteins encoded by ALK, EGLN3, and NUAK1 as drug targets, based upon a literature search and the gene annotations that indicated that these genes were expressed in cancer and had potentially functional binding pockets (e.g., protein kinase) for ligands. This evidence concerns the gene EGLN3 and cancer.